FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 276 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR ESMO Calls for Further EU Measures Enhancing Europe’s Clinical Trial Regulatory... June 16, 2026 Moving Beyond BMI: Low Muscle Mass May Affect Cancer Survival April 30, 2018 A New Study Suggests Screen Time Might Not Be The Worst... November 14, 2019 8-Year-Old Cancer Survivor Celebrates Recovery By Donating Her Birthday Gifts To... July 23, 2019 Load more HOT NEWS What Is Peripheral Neuropathy and How Can It Be Prevented or... Former WNBA Player, Current Georgia Tech Coach Tasha Butts Diagnosed with... Durvalumab Plus Chemotherapy Improves Survival in Small Cell Lung Cancer Alex Trebek Has Completed Chemo And Will Be Back For The...
